Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai

Background: There is very limited data on the experience and outcome of multidrug-resistant tuberculosis (MDR-TB) patients treated privately out of the DOTS plus program. Goal of this study is to provide characteristics and treatment outcomes of a prospective cohort of MDR-TB patients managed at a p...

Full description

Bibliographic Details
Main Authors: Zarir F Udwadia, Gautam Moharil
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2014-01-01
Series:Lung India
Subjects:
Online Access:http://www.lungindia.com/article.asp?issn=0970-2113;year=2014;volume=31;issue=4;spage=336;epage=341;aulast=Udwadia
id doaj-a679cd991315487d9ca48f9a9110fc02
record_format Article
spelling doaj-a679cd991315487d9ca48f9a9110fc022020-11-24T21:59:51ZengWolters Kluwer Medknow PublicationsLung India0970-21130974-598X2014-01-0131433634110.4103/0970-2113.142101Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in MumbaiZarir F UdwadiaGautam MoharilBackground: There is very limited data on the experience and outcome of multidrug-resistant tuberculosis (MDR-TB) patients treated privately out of the DOTS plus program. Goal of this study is to provide characteristics and treatment outcomes of a prospective cohort of MDR-TB patients managed at a private tertiary referral institute. Materials and Methods: A prospective analysis of a cohort of MDR-TB patients treated in a tertiary private hospital, with the back-up of a Level 2 mycobacterial laboratory, which has recently received recognition by the Revised National Tuberculosis Control Program (RNTCP) for second-line drug susceptibility (DST). All patients received an individualized MDR regimen on an ambulatory basis. Results: Our 68% success rates are respectable and show that given the right laboratory backing, MDR-TB can be managed successfully in selected private practice settings.http://www.lungindia.com/article.asp?issn=0970-2113;year=2014;volume=31;issue=4;spage=336;epage=341;aulast=UdwadiaIndiaindividualized regimensmultidrug-resistant tuberculosisprivate practitionersprivate sector
collection DOAJ
language English
format Article
sources DOAJ
author Zarir F Udwadia
Gautam Moharil
spellingShingle Zarir F Udwadia
Gautam Moharil
Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai
Lung India
India
individualized regimens
multidrug-resistant tuberculosis
private practitioners
private sector
author_facet Zarir F Udwadia
Gautam Moharil
author_sort Zarir F Udwadia
title Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai
title_short Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai
title_full Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai
title_fullStr Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai
title_full_unstemmed Multidrug-resistant-tuberculosis treatment in the Indian private sector: Results from a tertiary referral private hospital in Mumbai
title_sort multidrug-resistant-tuberculosis treatment in the indian private sector: results from a tertiary referral private hospital in mumbai
publisher Wolters Kluwer Medknow Publications
series Lung India
issn 0970-2113
0974-598X
publishDate 2014-01-01
description Background: There is very limited data on the experience and outcome of multidrug-resistant tuberculosis (MDR-TB) patients treated privately out of the DOTS plus program. Goal of this study is to provide characteristics and treatment outcomes of a prospective cohort of MDR-TB patients managed at a private tertiary referral institute. Materials and Methods: A prospective analysis of a cohort of MDR-TB patients treated in a tertiary private hospital, with the back-up of a Level 2 mycobacterial laboratory, which has recently received recognition by the Revised National Tuberculosis Control Program (RNTCP) for second-line drug susceptibility (DST). All patients received an individualized MDR regimen on an ambulatory basis. Results: Our 68% success rates are respectable and show that given the right laboratory backing, MDR-TB can be managed successfully in selected private practice settings.
topic India
individualized regimens
multidrug-resistant tuberculosis
private practitioners
private sector
url http://www.lungindia.com/article.asp?issn=0970-2113;year=2014;volume=31;issue=4;spage=336;epage=341;aulast=Udwadia
work_keys_str_mv AT zarirfudwadia multidrugresistanttuberculosistreatmentintheindianprivatesectorresultsfromatertiaryreferralprivatehospitalinmumbai
AT gautammoharil multidrugresistanttuberculosistreatmentintheindianprivatesectorresultsfromatertiaryreferralprivatehospitalinmumbai
_version_ 1725846970848772096